Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
閉経後5年以上経過した骨粗鬆症患者40例を対象に,リセドロネート単剤治療後2年間の尿中Ⅰ型コラーゲン架橋N-テロペプチド(NTX)の変動について検討した.治療開始後3カ月でNTXは低下し,2年後のNTX値は,40例中35例が基準値内(9.3~54.3)を示した.今回の結果から,リセドロネート単剤投与は早期に骨吸収マーカーを低下させ,その後2年間にわたり骨代謝回転を安定した範囲内に維持する効果が示された.しかし,約13%の症例においては,2年後に基準値を逸脱する症例が見られ,慎重な経過観察と他剤との併用を考慮すべきである.
Changes in the bone resorption marker urine NTX (typeⅠcollagen crosslinked N-telopeptide) were evaluated in 40 women with osteoporosis treated with risedronate (2.5 mg/day) for two years. NTX had markedly decreased at 3 months, and at 2 years the values in 35 of the patients were within the reference range (9.3-54.3nmolBCE/mmolCr). Risedronate decreased the bone resorption marker level in the early phase and maintained the values within the reference range for two years. In about 13% of the patients they were beyond the reference range, so that it might be took into account of calcium and vitamin D supplements in these cases.
Copyright © 2006, Igaku-Shoin Ltd. All rights reserved.